Validation & Intervention Testing for Aging, Longevity and Healthspan
NCT07923630, Phase 2, Not yet recruiting, The University of Texas Health Science Center at San Antonio
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Validation & Intervention Testing for Aging, Longevity and Healthspan | ClinicalTrials.gov |
| NCT number | NCT07923630 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 2 | ClinicalTrials.gov |
| Enrollment | 1,200 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | The University of Texas Health Science Center at San Antonio | ClinicalTrials.gov |
| Conditions | Aging, Functional Decline | ClinicalTrials.gov |
| Interventions | Dapagliflozin 10Mg Oral Tablet, Semaglutide oral, Placebo | ClinicalTrials.gov |
| First posted | 2026-11-06 | ClinicalTrials.gov |
| Last updated | 2026-11-06 | ClinicalTrials.gov |
Registered outcomes 16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Continuous Short Physical Performance Battery SPPB | Baseline to end of study (approximately 36 months) | This is a well-established objective measure of physical function that assesses standing balance, gait speed test, and repeated chair stands. The SPPB score ranges from 0 to 12, with higher scores indicating better lower extremity physical function. | ClinicalTrials.gov |
| Secondary | Physiological reserve | Baseline to end of study (approximately 36 months) | Measured as Cardio-Pulmonary Exercise Test (CPET) on a cycle ergometer to measure maximum oxygen consumption rate (VO2 peak) during exercise during a treadmill test on a stationary bicycle. | ClinicalTrials.gov |
| Other | 6-minute Walk Test | Baseline to end of study (approximately 36 months) | Distance walked at self-selected normal pace over 6 minutes | ClinicalTrials.gov |
| Other | Grip strength | Baseline to end of study (approximately 36 months) | Isometric hand grip strength during a 3-5 second period | ClinicalTrials.gov |
| Other | Montreal Cognitive Assessment (MOCA) | Baseline to end of study (approximately 36 months) | Participants will complete the MOCA a brief cognitive screening tool used to assess cognitive function on person or remotely, as applicable. Scores are calculated according to the standardized scoring procedures for the version administered, with higher scores indicating better cognitive function. | ClinicalTrials.gov |
| Other | Center for Epidemiological Studies Depression Scale (CES-D) | Baseline to end of study (approximately 36 months) | Total scores range from 0 to 60, with higher scores indicating greater depressive symptom burden. | ClinicalTrials.gov |
| Other | Glycosolated hemoglobin (HbA1c) | Baseline to end of study (approximately 36 months) | Percentage of glucose in hemoglobin averaged over a 3 month period | ClinicalTrials.gov |
| Other | Body weight | Baseline to end of study (approximately 36 months) | Body weight (kg) | ClinicalTrials.gov |
| Other | Body mass index (BMI) | Baseline to 36 weeks | Body mass index is calculated using weight (kg) and height (meters) | ClinicalTrials.gov |
| Other | Visual acuity | Baseline to end of study (approximately 36 months) | Measured using Snellen test | ClinicalTrials.gov |
| Other | Hearing thresholds (dB) | Baseline to end of study (approximately 36 months) | Hearing is tested using a hand-held portable audiometer at various frequencies. | ClinicalTrials.gov |
| Other | Pulmonary Function (FEV1) | Baseline to 36 months | Measure of peak expiratory flow (FEV1) using a portable spirometer. | ClinicalTrials.gov |
| Other | Fat free mass | Baseline to end of study (approximately 36 months) | Measured by Bioelectrical Impedance Analysis (BIA) | ClinicalTrials.gov |
| Other | Body fat percentage | Baseline to end of study (approximately 36 months) | Measured by Bioelectrical Impedance Analysis (BIA) | ClinicalTrials.gov |
| Other | Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) | Baseline to end of study (approximately 36 months) | calculated from fasting insulin and fasting glucose | ClinicalTrials.gov |
| Other | Nutritional Status | Baseline to end of study (approximately 36 months) | Mini Nutritional Assessment (MNA) is a 6-item screening tool with total scores ranging from 0 to 14. Scores of 12-14 indicate normal nutritional status, 8-11 indicate risk of malnutrition, and 0-7 indicate malnourished. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)